Search

Your search keyword '"Stölzel, Friedrich"' showing total 774 results

Search Constraints

Start Over You searched for: Author "Stölzel, Friedrich" Remove constraint Author: "Stölzel, Friedrich"
774 results on '"Stölzel, Friedrich"'

Search Results

3. Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

4. Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT

6. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

7. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

9. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

10. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

11. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

13. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

14. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia

15. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany

16. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

17. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

18. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

19. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

20. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

22. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

23. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

24. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

26. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT

27. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

28. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT

29. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis

30. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation

31. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

32. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

34. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

35. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

36. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

37. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

39. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany

41. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

43. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

44. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

46. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia - an EBMT registry analysis of 1540 patients

47. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

48. Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation

49. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

50. Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse

Catalog

Books, media, physical & digital resources